NK cells as recipients of cytokine signals

Natural Killer Cells

Volumn , Issue , 2010, Pages 189-201

  Loux, Tara J ^a   Lotze, Michael T ^b   Zeh, Herbert J ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862544579     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-370454-2.00014-4     Document Type: Chapter

References (129)

1. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., Nakanishi K., Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998, 9:143-150.
2. Ahmad A., Sharif-Askari E., Fawaz L., Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J Virol 2000, 74:7196-7203.
3. Ajuebor M.N., Wondimu Z., Hogaboam C.M., Le T., Proudfoot A.E., Swain M.G. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol 2007, 170:1975-1988.
4. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 2000, 12:59-63.
5. Ashour A.E., Lin X., Wang X., Turnquist H.R., Burns N.M., Tuli A., Sadanandam A., Suleiman K., Singh R.K., Talmadge J.E., Solheim J.C. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biol Ther 2007, 6:1206-1210.
6. Barr D., Belz G., Reading P., Wojtasiak M., Whitney P., Heath W., Carbone F., Brooks A. A role for plasmacytoid dendritic cells in the rapid IL-18-dependent activation of NK cells following HSV-1 infection. Eur J Immunol 2007, 37:1334-1342.
7. Biron C. Interferons alpha and beta as immune regulators - a new look. Immunity 2001, 14:661-664.
8. Bejarano M., de Waal Malefyt R., Abrams J., Bigler M., Bacchetta R., de Vries J., Roncarolo M. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1992, 4:1389-1397.
9. Berahovich R.D., Lai N.L., Wei Z., Lanier L.L., Schall T.J. Evidence for NK cell subsets based on chemokine receptor expression. J Immunol 2006, 177:7833-7840.
10. Bose A., Baral R. Natural killer cell mediated cytotoxicity of tumor cells initiated by neem leaf preparation is associated with CD40-CD40L-mediated endogenous production of interleukin-12. Hum Immunol 2007, 68:823-831.
11. Burkett P., Koka R., Chien M., Chai S., Boone D., Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004, 200:825-834.
12. Cao X., Shores E., Hu-Li J., Anver M., Kelsall B., Russell S., Drago J., Noguchi M., Grinberg A., Bloom E., et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995, 2:223-238.
13. Caraux A., Lu Q., Fernandez N., Riou S., DiSanto J., Raulet D., Lemke G., Roth C. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol 2006, 7:747-754.
14. Caraux A., Kim N., Bell S., Zompi S., Ranson T., Lesjean-Pottier S., Garcia-Ojeda M., Turner M., Colucci F. Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood 2006, 107:994-1002.
15. Carr D.J., Wuest T., Ash J. An increase in herpes simplex virus type 1 in the anterior segment of the eye is linked to a deficiency of NK cell infiltration in mice deficient in CXCR3. J Interferon Cytokine Res 2008, 28:245-251.
16. Carson W., Giri J., Lindemann M., Linett M., Ahdieh M., Paxton R., Anderson D., Eisemann J., Grabstein K., Caligiuri M. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994, 180:1395-1403.
17. Chaix J., Tessmer M., Hoebe K., Fuseri N., Ryffel B., Dalod M., Alexopoulou L., Beutler B., Brossay L., Vivier E., Walzer T. Cutting edge: priming of NK cell by IL-18. J Immunol 2008, 181:1627-1631.
18. Chan S., Perussia B., Gupta J., Kobayashi M., Pospisil M., Young H., Wolf S., Clark S., Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characteristics of the responder cells and synergy with other inducers. J Exp Med 1991, 173:869-879.
19. Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T., Tagawa M. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005, 115:437-442.
20. Coelho A.L., Schaller M.A., Benjamin C.F., Orlofsky A.Z., Hogaboam C.M., Kunkel S.L. The chemokines CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol 2007, 179:5474-5482.
21. Cooper M., Bush J., Fehniger T., VanDeusen J., Waite R., Liu Y., Aguila H., Caliguiri M. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002, 100:3633-3638.
22. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P., Skak K., Lundsgaard D., Frederiksen K.S., Thygesen O., McArthur G.A. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007, 13:3630-3636.
23. DiSanto J., Muller W., Guy-Grand D., Fischer A., Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A 1995, 92:377-381.
24. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P., Das A., Lopes A.R., Borrow P., Williams K., Humphreys E., Afford S., Adams D.H., Bertoletti A., Maini M.K. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007, 204:667-680.
25. Eriksen K.W., Sondergaard H., Woetmann A., Krejsgaard T., Skak K., Geisler C., Wasik M.A., Odum N. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol Immunol 2008, 46:812-820.
26. Fehniger T., Cooper M., Nuovo G., Cella M., Facchetti F., Colonna M., Caliguiri M. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
27. Ferlazzo G., Munz C. NK cell compartments and their activation by dendritic cells. J Immunol 2004, 172:1333-1339.
28. Ferlazzo G., Pack M., Thomas D., Paludan C., Schmid D., Strowig T., Bougras G., Muller W., Moretta L., Munz C. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A 2004, 101:16606-16611.
29. Figueiredo F., Commodaro A.G., de Camargo M.M., Rizzo L.V., Belfort R. NK1.1 cells downregulate murine endotoxin-induced uveitis following intraocular administration of interleukin-12. Scand J Immunol 2007, 66:329-334.
30. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., Petri A., Hansen L.T., McArthur G.A., Davis I.D., Skak K. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008, 57:1439-1449.
31. Gao J., Tsuda Y., Han M., Xu S., Kanagawa N., Hatanaka Y., tani Y., Mizuguchi H., Tsutsumi Y., Mayumi T., Okada N., Nakagawa S. NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy. Cancer Immunol Immunother 2009, 58:291-299.
32. Giuliani M., Giron-Michel J., Negrini S., Vacca P., Durali D., Caignard A., Le Bousse-Kerdiles C., Chouaib S., Devocelle A., Bahri R., Durrbach A., Taoufik Y., Ferrini S., Croce M., Mingari M.C., Moretta L., Azzarone B. Generation of a novel regulatory Nk cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One 2008, 3:e2441.
33. Gosselin J., Tomolu A., Gallo R., Flamand L. Interleukin-15 as an activator of natural killer cell-mediated antiviral response. Blood 1999, 94:4210-4219.
34. Grant L., Yao Z., Hedrich C., Wang F., Moorthy A., Wilson K., Ranatunga D., Bream J. Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun 2008, 9:316-327.
35. Gregoire C., Cognet C., Chasson L., Coupet C.A., Dalod M., Reboldi A., Marvel J., Sallusto F., Vivier E., Walzer T. Intrasplenic trafficking of natural killer cells is redirected by chemokines upon inflammation. Eur J Immunol 2008, 38:2076-2084.
36. Guia S., Cognet C., de Beaucoudrey L., Tessmer M., Jouanguy E., Berger C., Filipe-Santos O., Feinberg J., Camcioglu Y., Al Jumaar S., Al-Hajjar S., Stephan J., Fieschi C., Abel L., Brossay L., Casanova J., Vivier E. A role for interleukin-12/23 in the maturation of human natural killer and Cd56+ T cells in vivo. Blood 2008, 111:5008-5016.
37. Hanna J., Wald O., Goldman-Wohl D., Prus D., Markel G., Gazit R., Katz G., Haimov-Kochman R., Fujii N., Yagel S., Peled A., Mandelboim O. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16-human natural killer cells. Blood 2003, 102:1569-1577.
38. Hanna J., MussaffiH., Steuer G., Hanna S., Deeb M., Blau H., Arnon T.I., Weizman N., Mandelboim O. Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood 2005, 106:3465-3473.
39. Hojo S., Koizumi K., Tsuneyama K., Arita Y., Cui Z., Shinohara K., Minami T., Hasimoto I., Nakayama T., Sakurai H., Takano Y., Yoshie O., Tsukada K., Saiki I. High-level expression of chemokines CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007, 67:4725-4731.
40. Hokeness K., Kuziel W., Biron C., Salazar-Mather T. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol 2005, 174:1549-1556.
41. Huang D., Shi F.D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., He T.T., Weaver J.T., Ljunggren H.G., Biron C.A., Littman D.R., RansohoffR.M. The neuronal chemokines CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalitis within the central nervous system. FASEB J 2006, 20:896-905.
42. Hyakudomi M., Matsubara T., Hyakudomi R., Yamamoto T., Kinugasa S., Yamanoi A., Maruyama R., Tanaka T. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 2008, 15:1775-1782.
43. Hyodo Y., Matsui K., Hayashi N., Tsutsui H., Kasiwamura S., Yamauchi H., Hiroishi K., Takeda K., Tagawa Y., Iwakura Y., Kayagaki N., Kurimoto M., Okamura H., Hada T., Yagita H., Akira S., Nakanishi K., Higashino K. IL-18 upregulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999, 162:1662-1668.
44. Jamieson A., Isnard P., Dorfman J., Coles M., Raulet D. Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol 2004, 172:864-870.
45. Jiang Y., Zhang Z., Diao Y., Jin X., Shi W., Geng W., Dai D., Zhang M., Han X., Liu J., Wang y., Shang H. Expression of chemokines receptors on natural killer cells in HIV-infected individuals. Cell Immunol 2008, 251:19-24.
46. Karlmark K.R., Wasmuth H.E., Trautwien C., Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol 2008, 2:233-242.
47. Kawakami Y., Rosenberg S.A., Lotze M.T. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988, 168:2183-2191.
48. Kawakami Y., Custer M.C., Rosenberg S.A., Lotze M.T. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol 1989, 142:3452-3461.
49. Kennedy M., Glaccum M., Brown S., Butz E., Viney J., Embers M., Matsuki N., Charrier K., Sedger L., Willis C., Brasel K., Morrissey P., Stocking K., Schuh J., Joyce S., Peschon J. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:753-756.
50. Khan I.A., Thomas S.Y., Moretto M.M., Lee F.S., Islam S.A., Combe C., Schwartzman J.D., Luster A.D. CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection. PLoS Pathog 2006, 2:e49.
51. Kobayashi M., Fitz L., Ryan M., Hewick R., Clark S., Chan S., Loudon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845.
52. Kojima H., Takeuchi M., Ohta T., Nishida Y., Arai N., Ikeda M., Ikegami H., Kurimoto M. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem Biophys Res Commun 1998, 244:183-186.
53. Laouar Y., Sutterwala F.S., Gorelik L., Flavell R.A. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 2005, 6:600-607.
54. Liu L., Wang S., Shan B., Shao L., Sato A., Kawamura K., Li Q., Ma G., Tagawa M. IL-27-mediated activation of natural killer cells and inflammation produced antitumor effects for human oesophageal carcinoma cells. Scand J Immunol 2008, 68:22-29.
55. Lodolce J., Boone D., Chai S., Swain R., Dassopoulos T., Trettin S., Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
56. London L., Perussia B., Trinchieri G. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol 1986, 137:3845-3854.
57. Luo X., Yu Y., Liang A., Xie Y., Liu S., Guo J., Wang W., Qi R., An H., Zhang M., Xu H., Guo Z., Cao X. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell Mol Immunol 2004, 1:199-204.
58. Mailliard R.B., Alber S.M., Shen H., Watkins S.C., Kirkwood J.M., Herberman R.B., Kalinski P. IL-18-induced CD83+ CCR7+ NK helper cells. J Exp Med 2005, 202:941-953.
59. McKenna H., Miller R., Brasel K., Maraskovsky E., Maliszewski C., Pulendran B., Lynch D., Teepe M., Roux E., Smith J., et al. Targeted disruption of the flt3 ligand gene in mice affects multiple hematopoietic lineages, including natural killer cells, B lymphocytes, and dendritic cells. Blood 1996, 88:474a.
60. Meadows S.K., Eriksson M., Barber A., Sentman C.L. Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int Immunopharmacol 2006, 6:1020-1028.
61. Minagawa M., Watanabe H., Miyaji C., Tomiyama K., Shimura H., Ito A., Ito M., Domen J., Weissman I., Kawai K. Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor beta-chain-deficient mice. J Immunol 2002, 169:4153-4160.
62. Morris S.C., Orekhova T., Meadows M.J., Heidorn S.M., Yang J., Finkelman F.D. IL-4 induces in vivo production of IFN-gamma by NK and NKT cells. J Immunol 2006, 176:5299-5305.
63. Munz C., Dao T., Ferlazzo G., de Cos M., Goodman K., Young J. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005, 105:266-273.
64. Nguyen K., Cousens L., Doughty L., Pien G., Durbin J., Biron C. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat Immunol 2000, 1:70-76.
65. Nguyen K., Salazar-Mather T., Dalod M., Van Deusen J., Wei X., Liew F., Caligiuri M., Durbin J., Biron C. Coordinated and distinct roles for IFN-alpha beta, IL-12 and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002, 169:4279-4287.
66. Nishioka Y., Nishimura N., Suzuki Y., Sone S. Human monocyte-derived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur J Immunol 2001, 31:2633-2641.
67. Numasaki M., Tagawa M., Iwata F., Suzuki T., Nakamura A., Okada M., Iwakura Y., Aiba S., Yamaya M. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007, 178:5086-5098.
68. Oniki S., Nagai H., Horikawa T., Furukawa J., Belladonna M.L., Yoshimoto T., hara I., Nishigori C. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006, 66:6395-6404.
69. Orange J., Biron C. Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 1996, 156:4746-4756.
70. Ottoviani C., Nasorri F., Bedini C., de Pita O., Girolomoni G., Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006, 36:118-128.
71. Page K., Chaudhary D., Goldman S., Kasaian M. Natural killer cells from protein kinase C theta -/- mice stimulated with interleukin-12 are deficient in production of interferon-gamma. J Leukoc Biol 2008, 83:1267-1276.
72. Pallandre J.R., Krzewski K., Bedel R., Ryffel B., Caignard A., Rohrlich P.S., Pivot X., Tiberghien P., Zitvogel L., Strominger J.L., Borg C. Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation. Blood 2008, 112:4420-4424.
73. Peritt D., Robertson S., Gri G., Showe L., Aste-Amezaga M., Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998, 161:5821-5824.
74. Pien G., Satoskar A., Takeda K., Akira S., Biron C. Cutting edge: selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection. J Immunol 2000, 165:4787-4791.
75. Pokkali S., Das S.D., Selvaraj A. Differential upregulation of chemokines receptors on CD56(+) NK cells and their transmigration to the site of infection in tuberculous pleurisy. FEMS Immunol Med Microbiol 2009, 55:352-360.
76. Prlic M., Blazar B., Farrar M., Jameson S. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003, 197:967-976.
77. Qian C., Jiang X., An H., Yu Y., Guo Z., Liu S., Xu H., Cao X. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK cell activiation. Blood 2006, 108:2307-2315.
78. Ranson T., Vosshenrich C., CorcuffE., Richard O., Muller W., di Santo J. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003, 101:4887-4893.
79. Regunathan J., Chen y., Jutlesa S., Dai X., Bai L., Wen R., Wang D., Malarkannan S. Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells. J Immunol 2006, 177:5365-5376.
80. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006, 177:120-129.
81. Roda J.M., Joshi T., Butchar J.P., McAlees J.W., Lehman A., Tridandapani S., Carson W.E. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007, 13:6419-6428.
82. Sakthivel S.K., Singh U.P., Singh S., Taub D.D., Novakovic K.R., Lillard J.W. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J Immune Based Ther Vaccines 2008, 6:6.
83. Salazar-Mather T., Hokeness K. Calling in the troops: regulation of inflammatory cell trafficking through innate cytokine/chemokines networks. Viral Immunol 2006, 16:291-306.
84. Salazar-Mather T., Hamilton T., Biron C. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J Clin Invest 2000, 105:985-993.
85. Salcedo T., Azzoni L., Wolf S., Perussia B. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol 1993, 151:2511-2520.
86. Salcedo R., Stauffer J.K., Lincoln E., Back T.C., Hixon J.A., Hahn C., Shafer-Weaver K., Malyguine A., Kastelein R., Wigginton J.M. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004, 173:7170-7182.
87. Santoni A., Carlino C., Stabile H., Gismondi A. Mechanisms underlying recruitment and accumulation of decidual NK cells in uterus during pregnancy. Am J Reprod Immunol 2008, 59:417-424.
88. Sayos J., Nguyen K., Wu C., Stepp S., Howie D., Schatzle J., Kumar V., Biron C., Terhorst C. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 2000, 12:1749-1757.
89. Schwartz Y., Avraham R., Benish M., Rosenne E., Ben-Eliyahu S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res Treat 2008, 107:211-223.
90. Semino C., Angelini G., Poggi A., Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005, 106:609-616.
91. Semino C., Ceccarelli J., Lotti L., Torrisi M., Angelini G., Rubartelli A. The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion. J Leukoc Biol 2007, 81:92-99.
92. Singh U.P., Singh S., Singh R., Cong Y., Taub D.D., Lillard J.W. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10 (-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res 2008, 28:31-43.
93. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008, 123:575-583.
94. Smithgall M., Comeau M., Yoon B., Kaufman D., Armitage R., Smith D. IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cell, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
95. Sporri R., Joller N., Hilbi H., Oxenius A. A novel role for neutrophils as critical activators of NK cells. J Immunol 2008, 181:7121-7130.
96. Starnes T., Rasila K.K., Robertson M.J., Brahmi Z., Dahl R., Christopherson K., Hromas R. The chemokines CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 2006, 34:1101-1105.
97. Strbo N., de Armas L., Liu H., Kolber M.A., Lechtenheld M., Pahwa S. IL-21 augments natural killer effector functions in chronical HIV-infected individuals. AIDS 2008, 22:1551-1560.
98. Suzuki H., Duncan G., Takimoto H., Mak T. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med 1997, 185:499-505.
99. Swann J., Hayakawa Y., Zerafa N., Sheehan K., Scott B., Schreiber R., Hertzog P., Smyth M. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007, 178:7540-7549.
100. Takeda K., Tsutsui H., Yoshimoto T., Adachi O., Yoshida N., Kishimoto T., Okamura H., Nakanishi K., Akira S. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998, 8:383-390.
101. Terme M., Tomasello E., Maruyama K., Crepineau F., Chaput N., Flament C., Marolleau J., Angevin E., Wagner E., Salomon B., Lemmonier F., Wakasugi H., Colonna M., Vivier E., Zitvogel L. IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J Immunol 2004, 172:5957-5966.
102. Thapa M., Kuziel W.A., Carr D.J. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007, 81:3704-3713.
103. Thapa M., Welner R.S., Pelayo R., Carr D.J. CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous system. J Immunol 2008, 180:1098-1106.
104. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cell. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978, 147:1314-1333.
105. Trinchieri G., Matsumoto-Kobayashi M., Clark S., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984, 160:1147-1169.
106. Tripp C., Wolf S., Unanue E. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A 1993, 90:3725-3729.
107. Trotta R., Col J.D., Yu J., Ciarlariello D., Thomas B., Zhang X., Allard J., Wei M., Mao H., Byrd J.C., Perrotti D., Caliguiri M.A. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytoxicity in human NK cells. J Immunol 2008, 181:3784-3792.
108. Tsutsui H., Nakanishi K., Matsui K., Higashino K., Okamura H., Miyazawa Y., Kaneda K. IFN-g-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996, 157:3967-3973.
109. Tsutsui H., Matsui K., Kawada N., Hyodo Y., Hayashi N., Okamura H., Higashino K., Nakanishi K. IL-18 accounts for both TNF-a- and FasL-mediated hepatotoxic pathways in endotoxin-induced liver injury. J Immunol 1997, 159:3961.
110. Turnquist H.R., Lin X., Ashour A.E., Hollingsworth M.A., Singh R.K., Talmadge J.E., Solheim J.C. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncol 2007, 30:631-639.
111. Villarino A.V., Larkin J., Saris C.J., Caton A.J., Lucas S., Wong T., de Sauvage F.J., Hunter C.A. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol 2005, 174:7684-7691.
112. Wald O., Weiss I.D., Wald H., Shoham H., Bar-Shavit Y., Beider K., Galun E., Weiss L., Flaishon L., Shachar I., Nagler A., Lu B., Gerard C., Gao J.L., Mishani E., Farber J., Peled A. IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 2006, 176:4716-4729.
113. Waldmann T., Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999, 17:19-49.
114. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., Johnson M.G., Medina J.C., Collins T.L., Fulton A.M. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701-7707.
115. Walser T.C., Ma X., Kundu N., Dorsey R., Goloubeva O., Fulton A.M. Immune-mediated modulation of breast cancer growth and metastasis by the chemokines Mig (CXCL9) in a murine model. J Immunother 2007, 30:490-498.
116. Wendel M., Galani I.E., Suri-Payer E., Cerwenka A. Natural killer cell accumulation in tumors is dependent of IFN-gamma and CXCR3 ligands. Cancer Res 2008, 68:8437-8445.
117. Wendt K., Wilk E., Buyny S., Schmidt R., Jacobs R. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007, 122:486-495.
118. Willerford D., Chen J., Ferry J., Davidson L., Ma A., Alt F. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3:521-530.
119. Williams N., Klem J., Puzanov I., Sivakumar O., Bennett M., Kumar V. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J Immunol 1999, 163:2648-2656.
120. Wuest T.R., Carr D.J. Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection. J Immunol 2008, 181:7985-7993.
121. Yang S.C., Batra R.K., Hillinger S., Reckamp K.L., Strieter R.M., Dubinett S.M., Sharma S. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006, 66:3205-3213.
122. Yoshimoto T., Takeda K., Tanak T., Ohkusu K., Kasiwamura S., Okamura H., Akira S., Nakanishi K. IL-12 upregulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998, 161:3400-3407.
123. Young H., Ortaldo J. One-signal requirement for interferon-gamma production by human large granular lymphocytes. J Immunol 1987, 139:724-727.
124. Yu Y.R., Fong A.M., Combadiere C., Gao J.L., Murphy P.M., Patel D.D. Defective antitumor responses in CX3CR1-deficient mice. Int J Cancer 2007, 121:316-322.
125. Yuan J., Liu Z., Lim T., Zhang H., He J., Walker E., Shier C., Wang Y., Su Y., Sall A., McManus B., Yang D. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 2009, 104:628-638.
126. Zeng Y., Huebener N., Fest S., Weixler S., Schroeder U., Gaedicke G., Ziang R., Schramm A., Eggert A., Reisfeld R.A., Lode H.N. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007, 67:2331-2338.
127. Zhang X., Wei H., Wang H., Tian Z. Involvement of interaction between fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells. Oncol Rep 2006, 15:485-488.
128. Zhang X., Wei H., Chan Q., Tian Z. Activation of human natural killer cells by recombinant membrane-expressed fractalkine on the surface of tumor cells. Oncol Rep 2007, 17:1371-1375.
129. Zhang C., Zhang J., Niu J., Zhou Z., Zhang J., Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 2008, 69:490-500.